Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard/Collagen's Contigen

This article was originally published in The Gray Sheet

Executive Summary

The injectable collagen treatment for urinary incontinence will be marketed by Bard in kits containing six syringes, at a price of $1,800 per kit. The average patient requires treatment with six syringes; "The Gray Sheet," in a Oct. 4 story on the approval of the device (p. 1), said that Contigen could generate as much as $5,400 per treated patient based on clinical trial results showing that patients achieved continence in one to three treatment sessions, with each session requiring between one and six syringes.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel